Detection of residual Daudi tumor cells in the bone marrow of the paralyzed or the long-term survivor mice
| Treatment group . | Disease status . | N . | Murine cells (hCD19−), % . | Daudi B cells (hCD19+), % . |
|---|---|---|---|---|
| Untreated | 22 d | 3 | 52.4 | 47.6 ± 9.1 |
| Untreated | Paralyzed | 3 | 5.0 | 95.1 ± 3.1 |
| Dox naked liposomes | Paralyzed | 3 | 9.5 | 90.5 ± 3.3 |
| Dox-BPCNeuAc (2%) liposomes | Survivor | 3 | 99.7 | ND |
| Dox-BPCNeuAc (5%) liposomes | Survivor | 5 | 99.8 | ND |
| Treatment group . | Disease status . | N . | Murine cells (hCD19−), % . | Daudi B cells (hCD19+), % . |
|---|---|---|---|---|
| Untreated | 22 d | 3 | 52.4 | 47.6 ± 9.1 |
| Untreated | Paralyzed | 3 | 5.0 | 95.1 ± 3.1 |
| Dox naked liposomes | Paralyzed | 3 | 9.5 | 90.5 ± 3.3 |
| Dox-BPCNeuAc (2%) liposomes | Survivor | 3 | 99.7 | ND |
| Dox-BPCNeuAc (5%) liposomes | Survivor | 5 | 99.8 | ND |
ND indicates not detectable compared with isotype control (< 0.4%).